See the DrugPatentWatch profile for Strensiq
What is Strensiq?
Strensiq is a medicine used to treat X-linked hypophosphatemia (XLH) and other forms of hypophosphatemia in children and adults. It contains burosumab as the active ingredient, a monoclonal antibody that targets fibroblast growth factor 23 (FGF23). By blocking FGF23 activity, Strensiq helps increase phosphate levels in the body, which supports bone and teeth mineralization [1].
What does Strensiq treat (and who is it for)?
Strensiq is used for:
- X-linked hypophosphatemia (XLH), including in pediatric patients and adults [1].
- Other hypophosphatemic conditions where FGF23-driven phosphate wasting is a key problem (as defined in its prescribing information) [1].
How does Strensiq work?
Strensiq targets FGF23. FGF23 normally reduces phosphate reabsorption in the kidney and lowers vitamin D activity. By inhibiting FGF23, Strensiq increases serum phosphate and supports improved mineralization [1].
How is Strensiq given?
Strensiq is administered by injection. The exact dosing schedule depends on the patient’s age and weight and follows the regimen in the prescribing information [1].
What side effects do patients ask about?
Common side effects reported for Strensiq include injection-site reactions and upper respiratory or other nonspecific symptoms (with additional risks depending on the patient group and other medical factors) [1].
What do clinicians monitor during treatment?
Clinicians typically monitor blood phosphate and other labs to maintain phosphate in an appropriate range and reduce the risk of complications related to overcorrection or underlying disease progression [1].
How does Strensiq compare with other XLH treatments?
Strensiq differs from earlier XLH therapies such as phosphate supplements and active vitamin D analogs because it directly targets FGF23 signaling rather than supplementing phosphate and vitamin D. The choice between options depends on disease severity, age, kidney history, lab targets, and tolerance of prior therapies [1].
What to do if a dose is missed
If a dose is missed, the next dose is usually taken according to the prescribing information timing guidance. Patients should follow their clinician’s instructions or the product label for missed-dose steps [1].
Sources
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/strensiq